Japanese Government Procurement
a Aflibercept (genetical recombination) (40 mg/mL 0.278 mL/vial): approx. 1000 vials...
| Procuring Entity | Sapporo city |
|---|---|
| Category |
0004 Medical & Pharmaceutical Products |
Publication Date
Aug 04, 2017
| Deadline | Sep 25, 2017 |
|---|---|
| Summary |
Summary (1) Nature and quantity of the products to be procured: a Aflibercept (genetical recombination) (40 mg/mL 0.278 mL/vial): approx. 1000 vials b Infliximab (genetical recombination) (100 mg/ vial): approx. 810 vials c Lenalidomide hydrate capsule (5 mg + PTP40 capsules/case): approx. 170 cases d Palivizumab (genetical recombination) (100 mg/ vial): approx. 340 vials e Nivolumab (Genetical Recombination) (100 mg/ vial): approx. 140 vials f Golimumab (genetical recombination) (50 mg 0.5 mL/vial): approx. 360 vials g Etanercept (genetical recombination) (50 mg pen 1 mL * 2 kits/case): approx. 680 cases h Rituximab (genetical recombination) (500 mg 50 mL/vial): approx. 200 vials i Ranibizumab (genetical recombination) (10 mg/mL/kit): approx. 250 kits (2) Time limit for tender: 17:00 on September 25 (Mon), 2017 (3) Contact point for the notice: Management & Planning Section, Management Department, Management Office, Hospital Bureau, Sapporo Municipal Government, Kita 11-jo Nishi 13- chome, Chuo-ku, Sapporo 060-8604, Japan. TEL 011-726-2211 |
ID 07708b1e2d507fb7
